Biametrics GmbH Concludes Financing Round with 3.1 Million Euros
News Oct 10, 2015
Biametrics GmbH, which is based in Tübingen, Germany, has concluded a round of financing that has raised 3.1 million euros. LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW and KfW Bankengruppe were the main investors in the Series A round.
Together with founding investors High-Tech Gründerfonds HTGF and Seedfonds BW, who have supported the company since 2010, this fresh capital will be used to develop and market label-free analytical devices for the life sciences sector.
The analytical devices developed by Biametrics, which are based on patented 1-lambda RIDe technology, operate on a completely label-free basis, even at very low detection limits. Standard measurement processes using fluorescent dyes can have a significant influence on the activities of the biomolecules being investigated.
The new technology can be used, for example, to generate valuable data on the binding properties of biomolecules that are important, among other things, for the development of new pharmacological active ingredients. At the same time, the analytical sequences are robust, fast and low-cost, with measurement results available after just a few minutes.
The group of investors consisting of LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, KfW Bankengruppe, High-Tech Gründer-fonds HTGF and Seedfonds BW was impressed by the performance of the business, which was established five years ago in the STERN BioRegion by technical biologist Dr. Günther Proll and chemist Dr. Florian Pröll. The spin-off from the University of Tübingen has raised a total of 3.1 million euros to develop its innovative analytical devices, which utilize patent-protected surface chemistry that is based on years of development work.
1-lambda-RIDe technology detects the interactions between biomolecules. Materials with different optical properties partially reflect light at layer boundaries while allowing it to pass through at other areas. Where the reflected rays cause interference, i.e. superimpose each other, the reflected pattern changes. The measuring sensor reacts to this process. Light-permeable materials, such as glass or plastic with coated surfaces are used as consumables for the optical biosensors.
The Biametrics “b-screen” analytical device is being marketed in collaboration with partner Berthold Technologies GmbH & Co. KG (Bad Wildbad, Germany). As the device can be used to investigate up to 10,000 interactions per square centimetre in the shortest possible space of time, it is primarily ideal for high-throughput screening and for identifying new pharmaceutically relevant molecules on standard microarrays, as already being used in the area of fluorescence microarrays.
Meanwhile, the mobile b-portable can be used to take measurements directly at the point of need and obtain a result immediately. The analytical device can thus also be used for on-site monitoring in bioreactors or fermentation plants and in human and animal diagnostics. Passengers at airports can even be checked for virus particles in next to no time using this technology.
New Drug to Treat Herpes Simplex Virus Infection?News
Researchers have now identified a small drug molecule that can clear the HSV-1 infection in the cells of the cornea -- the clear outer layer of the eyeball -- and works completely differently than the currently-available drugs, making it a promising potential option for patients who have developed resistance.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Gaining a Deeper Understanding of Protein Kinases Involved in CancerNews
Vaccinia-related protein kinases VRK1 and VRK2, which are involved in cell proliferation, are considered potential targets for treatment of prostate, ovarian, colorectal and other kinds of cancer. To obtain a deeper understanding of the role of these enzymes in human cells, in the contexts of both wellness and disease, researchers are working on the development of small synthetic molecules capable of modulating their activity in study models.READ MORE